Related Experiment Video
Updated: Jun 16, 2026
15:05
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
EGFR signaling and drug discovery
Georg Lurje1, Heinz-Josef Lenz
1Department of Visceral- and Transplantation Surgery, University Hospital Zurich, Zurich, Switzerland.
Oncology
|February 5, 2010
Summary
Dysregulation of human epidermal growth factor receptor (ErbB/HER) pathways drives cancer progression. Targeted therapies like monoclonal antibodies and tyrosine kinase inhibitors show promise in blocking tumor growth and are approved for various cancers.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Dysregulation of human epidermal growth factor receptor (ErbB/HER) pathways, through overexpression or constitutive activation, contributes to tumor progression, including angiogenesis and metastasis, correlating with poor prognosis in malignancies.
- ErbB signaling is implicated not only in cancer but also in cardiovascular and neurodegenerative diseases.
Purpose of the Study:
- To review the role of ErbB pathways in cancer and the therapeutic potential of targeted inhibitors.
- To highlight approved anti-ErbB therapies and their clinical applications.
Main Methods:
- Review of scientific literature on ErbB pathway dysregulation and targeted therapies.
- Analysis of preclinical data (in vitro and xenograft models) and clinical outcomes of approved anti-ErbB agents.
Main Results:
- Inhibition of ErbB pathways using monoclonal antibodies (MoAbs) or tyrosine kinase inhibitors (TKIs) effectively blocks cell cycle progression, reduces pro-angiogenic factors, and induces apoptosis in various cancer models.
- Several anti-ErbB MoAbs and TKIs are approved for treating advanced colorectal cancer, head and neck squamous cell carcinoma, non-small-cell lung cancer, pancreatic cancer, and breast cancer.
Conclusions:
- The ErbB receptor family, particularly EGFR and HER-2, are validated therapeutic targets for anti-cancer strategies.
- Targeted ErbB-directed therapies have demonstrated significant clinical efficacy, although further research is warranted.
Related Concept Videos
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...